Evidence map›Paper›PMID 37265006›Full record

ArticleMolecular pharmaceutics2023

New Radiolabeled Exendin Analogues Show Reduced Renal Retention.

Lieke Joosten, Cathelijne Frielink, Theodorus J P Jansen, Daphne Lobeek, Fritz Andreae, Mark Konijnenberg, Sandra Heskamp, Martin Gotthardt, Maarten Brom

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Lieke JoostenDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-4427-8664
Cathelijne FrielinkDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Theodorus J P JansenDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Daphne LobeekDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Fritz AndreaeForschungs- und Entwicklungs GmbH, piCHEM, Parkring 3, 8074 Grambach, Austria.
Mark KonijnenbergDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Sandra HeskampDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0001-7250-0846
Martin GotthardtDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Maarten BromDepartment of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Radboud University Nijmegen · NLForschungs- und Beratungsstelle Arbeitswelt · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PET imaging of the glucagon-like peptide-1 receptor (GLP-1R) using radiolabeled exendin is a promising imaging method to detect insulinomas. However, high renal accumulation of radiolabeled exendin could hamper the detection of small insulinomas in proximity to the kidneys and limit its use as a radiotherapeutic agent. Here, we report two new exendin analogues for GLP-1R imaging and therapy, designed to reduce renal retention by incorporating a cleavable methionine-isoleucine (Met-Ile) linker. We examined the renal retention and insulinoma targeting properties of these new exendin analogues in a nude mouse model bearing subcutaneous GLP-1R-expressing insulinomas. NOTA or DOTA was conjugated via a methionine-isoleucine linker to the C-terminus of exendin-4 (NOTA-MI-exendin-4 or DOTA-MI-exendin-4). NOTA- and DOTA-exendin-4 without the linker were used as references. The affinity for GLP-1R was determined in a competitive binding assay using GLP-1R transfected cells. Biodistribution of [

Indexed as

InsulinomaPancreatic NeoplasmsAnimalsExenatideGallium RadioisotopesGlucagon-Like Peptide-1 ReceptorIsoleucineKidneyMethionineMiceMice, NudePositron-Emission TomographyPositron Emission Tomography Computed TomographyTissue DistributionExenatideGallium RadioisotopesGlucagon-Like Peptide-1 ReceptorIsoleucineMethionineexendinGa-68insulinomasLu-177PET/CTrenal retention

Identifiers

PMID37265006
PMCPMC10324399
OpenAlexW4379095634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.